CSL CEO and Managing Director Paul McKenzie says the time is right to spin off its Seqirus business as vaccine demand grows and “fatigue” fades in the US, especially among the ageing population. The Australian biotech giant’s shares plunged the most in 23 years after it reported disappointing earnings. (Source: Bloomberg)
www.bloomberg.com
#Vaccine #Fatigue #Fade #CSL #CEO
US Vaccine Fatigue Will Fade, CSL CEO Says
